Alnylam grants InterfeRx license to Sylentis
Both the companies will discover, develop and commercialize synthetic siRNA directed towards an undisclosed target for the treatment of glaucoma. Once Sylentis exercises this option, Alnylam will be
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.